Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Three distinct mechanisms of activation of

Published byΦωτινή Ἀλκμήνη Μακρή Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Three distinct mechanisms of activation of"— Presentation transcript:

1 Figure 2 Three distinct mechanisms of activation of
the epidermal growth factor receptor (EGFR) pathway Figure 2 | Three distinct mechanisms of activation of the epidermal growth factor receptor (EGFR) pathway. a | Ligand binding. Soluble ErbB ligands can bind and thereby activate their ErbB receptor (here EGFR) in an endocrine (distant cell), paracrine (neighbouring cell), or autocrine (same cell) way. b | Membrane-anchored ligands can activate ErbB receptors (here EGFR) present on membranes of adjacent cells (juxtacrine signalling). c | Transactivation of EGFR by G-protein coupled receptors (GPCRs). Of note, the cytoplasmic tail of the ligand is depicted in panels a and c. Harskamp, L. R. et al. (2016) The epidermal growth factor receptor pathway in chronic kidney diseases Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Figure 2 Three distinct mechanisms of activation of"

Similar presentations

Chapter 5.5-5.6.  Differentiate between the following:  Paracrine  Endocrine  Autocrine.

Chapter  Differentiate between the following:  Paracrine  Endocrine  Autocrine.
Cell Signaling: A Molecular View

Cell Signaling: A Molecular View
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 1 Pre-eclampsia prevents VEGF signalling in endothelial cells

Figure 1 Pre-eclampsia prevents VEGF signalling in endothelial cells
Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 1 Cellular processes involved in cancer development

Figure 1 Cellular processes involved in cancer development
Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Physiological changes in the renal system in pregnancy
Figure 2 Proinflammatory mechanisms in CKD

Figure 2 Proinflammatory mechanisms in CKD
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Pathways of complement activation

Figure 1 Pathways of complement activation
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.
Figure 7 The efficacy of phosphate-binder therapy

Figure 7 The efficacy of phosphate-binder therapy

Similar presentations

Ads by Google